The AMA Voted to Undo RFK Jr.’s Peptide Policy. Medspas Offering BPC-157 Are Building on a Policy That Can Disappear With One Memo.

The AMA Voted to Undo RFK Jr.’s Peptide Policy. Medspas Offering BPC-157 Are Building on a Policy That Can Disappear With One Memo.

The AMA Voted to Undo RFK Jr.’s Peptide Policy. Medspas Offering BPC-157 Are Building on a Policy That Can Disappear With One Memo.Dr. Kate Dee
Published on: 19/11/2026

The AMA voted to urge HHS to rescind RFK Jr.'s peptide policy. What it means for medspas offering BPC-157, and why the policy can disappear with one memo.

AMA peptide policyBPC-157TB-500compounded peptidesHHS enforcement discretionRFK Jr. peptidespeptide compounding503A compoundingunapproved peptidesmedspa peptidesHims & Hers peptidesFDA Pharmacy Compounding Advisory Committeestate medical board peptidesmedspa complianceMedSpa Board certification
Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.

Peptides Are Not Being Approved. They May Be Allowed. That Is Not the Same Thing.Dr. Kate Dee
Published on: 21/10/2026

An FDA peptide compounding policy is under review. It is not approval. What medspas need to know about BPC-157, enforcement discretion, and prescriber risk.

FDA peptidespeptide interim access policycompounded peptidesBPC-157BPC-157 legalpeptide therapy medspaenforcement discretion503A bulks listTB-500research use only peptidespeptide safetycompounding pharmacymedspa complianceunapproved drugsMedSpa Board